HCA Healthcare Reports Third Quarter 2021 Results; Revises 2021 Guidance
HCA Healthcare reported strong third-quarter results for 2021, with revenues of $15.276 billion, up from $13.311 billion in 2020. Net income soared to $2.269 billion, or $7.00 per diluted share, compared to $668 million or $1.95 per diluted share last year. Adjusted EBITDA rose to $3.224 billion. Despite increased admissions (6.8%) and emergency room visits (31.2%), inpatient surgeries declined by 4.9%. HCA also declared a quarterly dividend of $0.48 per share. The company revised its 2021 guidance, expecting revenues between $58.7 billion and $59.3 billion.
- Revenue increase from $13.311 billion to $15.276 billion YoY.
- Net income jumped to $2.269 billion, from $668 million YoY.
- Adjusted EBITDA increased to $3.224 billion, up from $2.053 billion YoY.
- Same facility admissions grew by 6.8%, and emergency room visits surged by 31.2%.
- Quarterly dividend declared at $0.48 per share.
- Revised 2021 guidance for revenues set between $58.7 billion and $59.3 billion.
- Inpatient surgeries declined by 4.9% YoY.
- Cash flows from operating activities decreased from $2.717 billion to $2.277 billion YoY.
Key third quarter metrics (all percentage changes compare 3Q 2021 to 3Q 2020 unless otherwise noted):
-
Revenues totaled
$15.27 6 billion -
Net income attributable to
HCA Healthcare, Inc. totaled , or$2.26 9 billion per diluted share$7.00 -
Adjusted EBITDA totaled
$3.22 4 billion -
Cash flows from operating activities totaled
$2.27 7 billion - Same facility admissions and same facility equivalent admissions increased 6.8 percent and 9.3 percent, respectively
“During the third quarter we experienced the most intense surge yet of the pandemic, and our colleagues and physicians delivered record levels of patient care to meet the demand caused by the Delta variant,” said
Revenues in the third quarter of 2021 increased to
For the third quarter of 2021, Adjusted EBITDA totaled
Same facility admissions and equivalent admissions increased 6.8 percent and 9.3 percent, respectively, in the third quarter of 2021, compared to the prior year period. Same facility emergency room visits increased 31.2 percent in the third quarter of 2021, compared to the prior year period. Same facility inpatient surgeries declined 4.9 percent, and same facility outpatient surgeries increased 6.4 percent in the third quarter of 2021, compared to the same period of 2020. Same facility revenue per equivalent admission increased 5.2 percent in the third quarter of 2021, compared to the third quarter of 2020, due to increases in acuity of patients treated and favorable payer mix in the quarter.
Because of the pandemic-related impact on volumes in the third quarter of 2020, the Company believes a comparison of volume statistics to the comparable period in 2019 provides additional context to the improvement in operations during 2021. The following table provides a summary of statistical measures for the third quarter of 2021 compared to the same period in 2019 on a same facility basis.
Third Quarter |
|||||||||
|
2021 |
2019 |
% Change |
||||||
Same Facility: | |||||||||
Admissions | 531,032 |
|
517,151 |
|
2.7 |
% |
|||
Equivalent Admissions | 892,665 |
|
897,774 |
|
-0.6 |
% |
|||
|
|
|
|
|
|||||
2,836,248 |
|
2,482,756 |
|
14.2 |
% |
||||
Equivalent |
4,767,733 |
|
4,310,064 |
|
10.6 |
% |
|||
|
|
|
|
|
|||||
Inpatient Surgery Cases | 125,533 |
|
141,313 |
|
-11.2 |
% |
|||
Outpatient Surgery Cases | 242,450 |
|
241,019 |
|
0.6 |
% |
|||
|
|
|
|
|
|||||
Emergency Room Visits | 2,301,968 |
|
2,198,357 |
|
4.7 |
% |
|||
Nine Months Ended
Revenues for the nine months ended
Balance Sheet and Cash Flows from Operations
As of
During the third quarter of 2021, the Company repurchased 9.605 million shares of its common stock at a cost of
Dividend
HCA today announced that its Board of Directors declared a quarterly cash dividend of
The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition and results of operations and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations.
2021 Revised Guidance
The 2021 guidance ranges for the year have been revised from our second quarter release and are as follows:
|
2021 |
|
Revenues |
|
|
Adjusted EBITDA |
|
|
EPS (diluted) |
|
|
Capital Expenditures |
Approximately |
The Company’s 2021 guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding the impact of the COVID-19 pandemic and related government legislation, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.
Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to
The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”
Earnings Conference Call
About the Company
As of
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company’s financial guidance for the year ending
All references to “Company” and “HCA Healthcare” as used throughout this release refer to
Condensed Consolidated Comprehensive Income Statements | |||||||||||||||||
Third Quarter | |||||||||||||||||
(Dollars in millions, except per share amounts) | |||||||||||||||||
2021 |
|
2020 |
|||||||||||||||
Amount |
|
Ratio |
|
Amount |
|
Ratio |
|||||||||||
Revenues | $ |
15,276 |
|
100.0 |
|
% |
$ |
13,311 |
|
100.0 |
|
% |
|||||
Salaries and benefits |
|
7,094 |
|
46.4 |
|
|
6,097 |
|
45.8 |
|
|||||||
Supplies |
|
2,463 |
|
16.1 |
|
|
2,128 |
|
16.0 |
|
|||||||
Other operating expenses |
|
2,530 |
|
16.6 |
|
|
2,251 |
|
16.9 |
|
|||||||
Government stimulus income reversal |
|
- |
|
- |
|
|
822 |
|
6.2 |
|
|||||||
Equity in earnings of affiliates |
|
(35 |
) |
(0.2 |
) |
|
(40 |
) |
(0.3 |
) |
|||||||
Depreciation and amortization |
|
716 |
|
4.7 |
|
|
694 |
|
5.2 |
|
|||||||
Interest expense |
|
398 |
|
2.6 |
|
|
385 |
|
2.9 |
|
|||||||
Gains on sales of facilities |
|
(1,047 |
) |
(6.9 |
) |
|
(14 |
) |
(0.1 |
) |
|||||||
|
12,119 |
|
79.3 |
|
|
12,323 |
|
92.6 |
|
||||||||
Income before income taxes |
|
3,157 |
|
20.7 |
|
|
988 |
|
7.4 |
|
|||||||
Provision for income taxes |
|
685 |
|
4.5 |
|
|
209 |
|
1.5 |
|
|||||||
Net income |
|
2,472 |
|
16.2 |
|
|
779 |
|
5.9 |
|
|||||||
Net income attributable to noncontrolling interests |
|
203 |
|
1.3 |
|
|
111 |
|
0.9 |
|
|||||||
Net income attributable to |
$ |
2,269 |
|
14.9 |
|
$ |
668 |
|
5.0 |
|
|||||||
Diluted earnings per share | $ |
7.00 |
|
$ |
1.95 |
|
|||||||||||
Shares used in computing diluted earnings per share (millions) |
|
324.029 |
|
|
343.346 |
|
|||||||||||
Comprehensive income attributable to |
$ |
2,252 |
|
$ |
715 |
|
|||||||||||
Condensed Consolidated Comprehensive Income Statements | |||||||||||||||||
For the Nine Months Ended |
|||||||||||||||||
(Dollars in millions, except per share amounts) | |||||||||||||||||
2021 |
|
2020 |
|||||||||||||||
Amount |
|
Ratio |
|
Amount |
|
Ratio |
|||||||||||
Revenues | $ |
43,688 |
|
100.0 |
|
% |
$ |
37,240 |
|
100.0 |
|
% | |||||
Salaries and benefits |
|
19,780 |
|
45.3 |
|
|
17,545 |
|
47.1 |
|
|||||||
Supplies |
|
7,067 |
|
16.2 |
|
|
5,999 |
|
16.1 |
|
|||||||
Other operating expenses |
|
7,424 |
|
17.0 |
|
|
6,825 |
|
18.3 |
|
|||||||
Equity in earnings of affiliates |
|
(78 |
) |
(0.2 |
) |
|
(48 |
) |
(0.1 |
) |
|||||||
Depreciation and amortization |
|
2,125 |
|
4.8 |
|
|
2,059 |
|
5.6 |
|
|||||||
Interest expense |
|
1,168 |
|
2.7 |
|
|
1,201 |
|
3.2 |
|
|||||||
Losses (gains) on sales of facilities |
|
(1,057 |
) |
(2.4 |
) |
|
6 |
|
- |
|
|||||||
Losses on retirement of debt |
|
12 |
|
- |
|
|
295 |
|
0.8 |
|
|||||||
|
36,441 |
|
83.4 |
|
|
33,882 |
|
91.0 |
|
||||||||
Income before income taxes |
|
7,247 |
|
16.6 |
|
|
3,358 |
|
9.0 |
|
|||||||
Provision for income taxes |
|
1,531 |
|
3.5 |
|
|
665 |
|
1.8 |
|
|||||||
Net income |
|
5,716 |
|
13.1 |
|
|
2,693 |
|
7.2 |
|
|||||||
Net income attributable to noncontrolling interests |
|
574 |
|
1.3 |
|
|
365 |
|
0.9 |
|
|||||||
Net income attributable to |
$ |
5,142 |
|
11.8 |
|
$ |
2,328 |
|
6.3 |
|
|||||||
Diluted earnings per share | $ |
15.43 |
|
$ |
6.79 |
|
|||||||||||
Shares used in computing diluted earnings per share (millions) |
|
333.248 |
|
|
343.014 |
|
|||||||||||
Comprehensive income attributable to |
$ |
5,152 |
|
$ |
2,273 |
|
Condensed Consolidated Balance Sheets | ||||||||||||
(Dollars in millions) | ||||||||||||
|
|
|
|
|
||||||||
2021 |
|
2021 |
|
2020 |
||||||||
ASSETS | ||||||||||||
Current assets: | ||||||||||||
Cash and cash equivalents | $ |
1,027 |
|
$ |
1,120 |
|
$ |
1,793 |
|
|||
Accounts receivable |
|
8,433 |
|
|
7,636 |
|
|
7,051 |
|
|||
Inventories |
|
2,019 |
|
|
2,027 |
|
|
2,025 |
|
|||
Other |
|
1,769 |
|
|
1,692 |
|
|
1,464 |
|
|||
|
13,248 |
|
|
12,475 |
|
|
12,333 |
|
||||
Property and equipment, at cost |
|
50,695 |
|
|
50,698 |
|
|
49,317 |
|
|||
Accumulated depreciation |
|
(27,148 |
) |
|
(27,227 |
) |
|
(26,118 |
) |
|||
|
23,547 |
|
|
23,471 |
|
|
23,199 |
|
||||
Investments of insurance subsidiaries |
|
418 |
|
|
410 |
|
|
388 |
|
|||
Investments in and advances to affiliates |
|
412 |
|
|
382 |
|
|
422 |
|
|||
|
9,153 |
|
|
8,680 |
|
|
8,578 |
|
||||
Right-of-use operating lease assets |
|
2,099 |
|
|
2,118 |
|
|
2,024 |
|
|||
Other |
|
685 |
|
|
628 |
|
|
546 |
|
|||
$ |
49,562 |
|
$ |
48,164 |
|
$ |
47,490 |
|
||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||
Current liabilities: | ||||||||||||
Accounts payable | $ |
3,759 |
|
$ |
3,531 |
|
$ |
3,535 |
|
|||
Accrued salaries |
|
2,134 |
|
|
1,896 |
|
|
1,720 |
|
|||
Other accrued expenses |
|
3,481 |
|
|
2,935 |
|
|
3,240 |
|
|||
Long-term debt due within one year |
|
250 |
|
|
253 |
|
|
209 |
|
|||
|
9,624 |
|
|
8,615 |
|
|
8,704 |
|
||||
Long-term debt, less debt issuance costs and discounts of |
|
32,049 |
|
|
32,319 |
|
|
30,795 |
|
|||
Professional liability risks |
|
1,522 |
|
|
1,585 |
|
|
1,486 |
|
|||
Right-of-use operating lease obligations |
|
1,742 |
|
|
1,767 |
|
|
1,673 |
|
|||
Income taxes and other liabilities |
|
2,800 |
|
|
2,088 |
|
|
1,940 |
|
|||
Stockholders' equity: | ||||||||||||
Stockholders' (deficit) equity attributable to |
|
(695 |
) |
|
(593 |
) |
|
572 |
|
|||
Noncontrolling interests |
|
2,520 |
|
|
2,383 |
|
|
2,320 |
|
|||
|
1,825 |
|
|
1,790 |
|
|
2,892 |
|
||||
$ |
49,562 |
|
$ |
48,164 |
|
$ |
47,490 |
|
||||
Condensed Consolidated Statements of Cash Flows | ||||||||
For the Nine Months Ended |
||||||||
(Dollars in millions) | ||||||||
2021 |
2020 |
|||||||
Cash flows from operating activities: | ||||||||
Net income | $ |
5,716 |
|
$ |
2,693 |
|
||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Increase (decrease) in cash from operating assets and liabilities: | ||||||||
Accounts receivable |
|
(1,312 |
) |
|
930 |
|
||
Inventories and other assets |
|
(333 |
) |
|
(36 |
) |
||
Accounts payable and accrued expenses |
|
731 |
|
|
542 |
|
||
Government stimulus refund liability |
|
- |
|
|
6,123 |
|
||
Depreciation and amortization |
|
2,125 |
|
|
2,059 |
|
||
Income taxes |
|
185 |
|
|
(114 |
) |
||
Losses (gains) on sales of facilities . |
|
(1,057 |
) |
|
6 |
|
||
Losses on retirement of debt |
|
12 |
|
|
295 |
|
||
Amortization of debt issuance costs and discounts |
|
21 |
|
|
22 |
|
||
Share-based compensation |
|
341 |
|
|
229 |
|
||
Other |
|
87 |
|
|
66 |
|
||
Net cash provided by operating activities |
|
6,516 |
|
|
12,815 |
|
||
Cash flows from investing activities: | ||||||||
Purchase of property and equipment |
|
(2,385 |
) |
|
(2,087 |
) |
||
Acquisition of hospitals and health care entities |
|
(488 |
) |
|
(380 |
) |
||
Sales of hospitals and health care entities |
|
1,980 |
|
|
68 |
|
||
Change in investments |
|
(38 |
) |
|
(40 |
) |
||
Other |
|
2 |
|
|
(44 |
) |
||
Net cash used in investing activities |
|
(929 |
) |
|
(2,483 |
) |
||
Cash flows from financing activities: | ||||||||
Issuances of long-term debt |
|
4,337 |
|
|
2,700 |
|
||
Net change in revolving credit facilities |
|
500 |
|
|
(2,480 |
) |
||
Repayment of long-term debt |
|
(3,787 |
) |
|
(3,403 |
) |
||
Distributions to noncontrolling interests |
|
(501 |
) |
|
(393 |
) |
||
Payment of debt issuance costs |
|
(38 |
) |
|
(35 |
) |
||
Payment of dividends |
|
(476 |
) |
|
(153 |
) |
||
Repurchase of common stock |
|
(6,143 |
) |
|
(441 |
) |
||
Other |
|
(241 |
) |
|
(156 |
) |
||
Net cash used in financing activities |
|
(6,349 |
) |
|
(4,361 |
) |
||
Effect of exchange rate changes on cash and cash equivalents |
|
(4 |
) |
|
(4 |
) |
||
Change in cash and cash equivalents |
|
(766 |
) |
|
5,967 |
|
||
Cash and cash equivalents at beginning of period |
|
1,793 |
|
|
621 |
|
||
Cash and cash equivalents at end of period | $ |
1,027 |
|
$ |
6,588 |
|
||
Interest payments | $ |
1,127 |
|
$ |
1,230 |
|
||
Income tax payments, net | $ |
1,346 |
|
$ |
779 |
|
||
|
||||||||||||||||
Operating Statistics |
||||||||||||||||
|
|
|
For the Nine Months |
|||||||||||||
Third Quarter |
|
|
Ended |
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||||
Operations: | ||||||||||||||||
Number of Hospitals |
|
183 |
|
|
187 |
|
|
183 |
|
|
187 |
|
||||
Number of Freestanding Outpatient Surgery Centers* |
|
123 |
|
|
121 |
|
|
123 |
|
|
121 |
|
||||
Licensed Beds at End of Period |
|
48,950 |
|
|
49,473 |
|
|
48,950 |
|
|
49,473 |
|
||||
Weighted Average Beds in Service |
|
42,088 |
|
|
42,426 |
|
|
42,304 |
|
|
42,304 |
|
||||
Reported: | ||||||||||||||||
Admissions |
|
536,848 |
|
|
506,756 |
|
|
1,575,269 |
|
|
1,487,992 |
|
||||
% Change |
|
5.9 |
% |
|
5.9 |
% |
||||||||||
Equivalent Admissions |
|
905,627 |
|
|
835,576 |
|
|
2,654,328 |
|
|
2,447,747 |
|
||||
% Change |
|
8.4 |
% |
|
8.4 |
% |
||||||||||
Revenue per Equivalent Admission | $ |
16,868 |
|
$ |
15,930 |
|
$ |
16,459 |
|
$ |
15,214 |
|
||||
% Change |
|
5.9 |
% |
|
8.2 |
% |
||||||||||
Inpatient Revenue per Admission | $ |
18,102 |
|
$ |
16,265 |
|
$ |
17,115 |
|
$ |
15,531 |
|
||||
% Change |
|
11.3 |
% |
|
10.2 |
% |
||||||||||
|
2,865,220 |
|
|
2,593,139 |
|
|
8,166,211 |
|
|
7,476,794 |
|
|||||
% Change |
|
10.5 |
% |
|
9.2 |
% |
||||||||||
Equivalent |
|
4,833,197 |
|
|
4,275,481 |
|
|
13,760,066 |
|
|
12,299,326 |
|
||||
% Change |
|
13.0 |
% |
|
11.9 |
% |
||||||||||
Inpatient Surgery Cases |
|
126,436 |
|
|
133,492 |
|
|
390,486 |
|
|
387,228 |
|
||||
% Change |
|
-5.3 |
% |
|
0.8 |
% |
||||||||||
Outpatient Surgery Cases |
|
249,192 |
|
|
232,493 |
|
|
742,527 |
|
|
629,723 |
|
||||
% Change |
|
7.2 |
% |
|
17.9 |
% |
||||||||||
Emergency Room Visits |
|
2,338,180 |
|
|
1,813,661 |
|
|
6,308,386 |
|
|
5,594,484 |
|
||||
% Change |
|
28.9 |
% |
|
12.8 |
% |
||||||||||
Outpatient Revenues as a Percentage of Patient Revenues |
|
34.1 |
% |
|
35.5 |
% |
|
36.0 |
% |
|
35.0 |
% |
||||
Average Length of Stay (days) |
|
5.337 |
|
|
5.117 |
|
|
5.184 |
|
|
5.025 |
|
||||
Occupancy (weighted average beds in service) |
|
74.0 |
% |
|
66.4 |
% |
|
70.7 |
% |
|
64.5 |
% |
||||
Same Facility: | ||||||||||||||||
Admissions |
|
531,032 |
|
|
497,309 |
|
|
1,549,732 |
|
|
1,458,609 |
|
||||
% Change |
|
6.8 |
% |
|
6.2 |
% |
||||||||||
Equivalent Admissions |
|
892,665 |
|
|
817,079 |
|
|
2,603,550 |
|
|
2,392,119 |
|
||||
% Change |
|
9.3 |
% |
|
8.8 |
% |
||||||||||
Revenue per Equivalent Admission | $ |
16,799 |
|
$ |
15,962 |
|
$ |
16,456 |
|
$ |
15,247 |
|
||||
% Change |
|
5.2 |
% |
|
7.9 |
% |
||||||||||
Inpatient Revenue per Admission | $ |
18,055 |
|
$ |
16,323 |
|
$ |
17,148 |
|
$ |
15,610 |
|
||||
% Change |
|
10.6 |
% |
|
9.9 |
% |
||||||||||
Inpatient Surgery Cases |
|
125,533 |
|
|
131,957 |
|
|
386,190 |
|
|
382,121 |
|
||||
% Change |
|
-4.9 |
% |
|
1.1 |
% |
||||||||||
Outpatient Surgery Cases |
|
242,450 |
|
|
227,918 |
|
|
724,914 |
|
|
616,082 |
|
||||
% Change |
|
6.4 |
% |
|
17.7 |
% |
||||||||||
Emergency Room Visits |
|
2,301,968 |
|
|
1,753,887 |
|
|
6,162,206 |
|
|
5,419,887 |
|
||||
% Change |
|
31.2 |
% |
|
13.7 |
% |
* Excludes freestanding endoscopy centers (21 centers at both |
Supplemental Non-GAAP Disclosures | |||||||||||||||||||||||||
Operating Results Summary | |||||||||||||||||||||||||
(Dollars in millions, except per share amounts) | |||||||||||||||||||||||||
|
|
|
|
For the Nine Months |
|||||||||||||||||||||
Third Quarter |
|
Ended |
|||||||||||||||||||||||
2021 |
|
2020 |
|
2021 |
|
2020 |
|||||||||||||||||||
Revenues | $ |
15,276 |
|
$ |
13,311 |
|
$ |
43,688 |
|
$ |
37,240 |
|
|||||||||||||
Net income attributable to |
$ |
2,269 |
|
$ |
668 |
|
$ |
5,142 |
|
$ |
2,328 |
|
|||||||||||||
Losses (gains) on sales of facilities (net of tax) |
|
(788 |
) |
|
(10 |
) |
|
(795 |
) |
|
9 |
|
|||||||||||||
Losses on retirement of debt (net of tax) |
|
- |
|
|
- |
|
|
9 |
|
|
227 |
|
|||||||||||||
Net income attributable to |
|
1,481 |
|
|
658 |
|
|
4,356 |
|
|
2,564 |
|
|||||||||||||
Depreciation and amortization |
|
716 |
|
|
694 |
|
|
2,125 |
|
|
2,059 |
|
|||||||||||||
Interest expense |
|
398 |
|
|
385 |
|
|
1,168 |
|
|
1,201 |
|
|||||||||||||
Provision for income taxes |
|
426 |
|
|
205 |
|
|
1,272 |
|
|
730 |
|
|||||||||||||
Net income attributable to noncontrolling interests |
|
203 |
|
|
111 |
|
|
574 |
|
|
365 |
|
|||||||||||||
Adjusted EBITDA (a) | $ |
3,224 |
|
$ |
2,053 |
|
$ |
9,495 |
|
$ |
6,919 |
|
|||||||||||||
Adjusted EBITDA margin (a) |
|
21.1 |
% |
|
15.4 |
% |
|
21.7 |
% |
|
18.6 |
% |
|||||||||||||
Diluted earnings per share: | |||||||||||||||||||||||||
Net income attributable to |
$ |
7.00 |
|
$ |
1.95 |
|
$ |
15.43 |
|
$ |
6.79 |
|
|||||||||||||
Losses (gains) on sales of facilities |
|
(2.43 |
) |
|
(0.03 |
) |
|
(2.39 |
) |
|
0.03 |
|
|||||||||||||
Losses on retirement of debt |
|
- |
|
|
- |
|
|
0.03 |
|
|
0.66 |
|
|||||||||||||
Net income attributable to |
$ |
4.57 |
|
$ |
1.92 |
|
$ |
13.07 |
|
$ |
7.48 |
|
|||||||||||||
Shares used in computing diluted earnings per share (millions) |
|
324.029 |
|
|
343.346 |
|
|
333.248 |
|
|
343.014 |
|
|||||||||||||
(a) |
Net income attributable to |
||||||||||||||||||
Management and investors review both the overall performance (including net income attributable to |
|||||||||||||||||||
Net income attributable to |
Supplemental Non-GAAP Disclosures | ||||||
2021 Operating Results Forecast | ||||||
(Dollars in millions, except per share amounts) | ||||||
For the Year Ending |
||||||
|
||||||
Low |
|
High |
||||
Revenues | $ |
58,700 |
$ |
59,300 |
||
Net income attributable to |
$ |
5,650 |
$ |
5,830 |
||
Depreciation and amortization |
|
2,840 |
|
2,860 |
||
Interest expense |
|
1,560 |
|
1,580 |
||
Provision for income taxes |
|
1,700 |
|
1,750 |
||
Net income attributable to noncontrolling interests |
|
750 |
|
780 |
||
Adjusted EBITDA (a) (b) | $ |
12,500 |
$ |
12,800 |
||
Diluted earnings per share: | ||||||
Net income attributable to |
$ |
17.20 |
$ |
17.80 |
||
Shares used in computing diluted earnings per share (millions) |
|
329.000 |
|
329.000 |
||
The Company's forecasted guidance range is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks. | ||||||||||||||
(a) |
The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy. |
|||||||||||||
(b) |
Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles ("GAAP"). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams. |
|||||||||||||
Management and investors review both the overall performance (including net income attributable to |
||||||||||||||
Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211022005081/en/
INVESTOR CONTACT:
615-344-2688
MEDIA CONTACT:
615-344-1851
Source:
FAQ
What were HCA's revenues for the third quarter of 2021?
What was the net income reported by HCA for Q3 2021?
How did HCA's Adjusted EBITDA change in Q3 2021?
What is the declared dividend per share by HCA for Q4 2021?